Drug based treatment of metastatic prostate cancer using recently approved drugs like Provenge and Yervoy have shown a considerable increase in the survival rates.
Robotic Prostatectomy Device
Drug- based treatment, however, has its limitations in being effective only in some clinical cases and also the high costs, into which they run into. Another drawback with using drugs to treat prostate cancer is that their immuno-modulatory effect is not powerful enough to destroy all the cancer cells in the body. In the words of Dr. David Samadi, the drugs are not capable of complete eradication of the cancer cells and when used for longer durations the cancer cells gain immunity over the drug. Dr. Samadi is the Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center and specialises in robotic surgery and prostate cancer treatment.
Robotic surgery for treating prostate cancer has shown the highest success rate that any primary treatment can provide. Robotic Prostatectomy causes minimum side effects and recovery time is short when compared with other conventional methods of treatment. With the help of SMART Surgery (Samadi Modified Advanced Robotic Technique), Dr. Samadi successfully preserves the delicate nerves that are responsible for the urinary control and sexual function. By treating prostate cancer through SMART surgery, he is able to cure 97% of his patients completely.